Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Antineoplastic Combined Chemotherapy Protocols
  • Neoadjuvant Therapy
  • Prostatic Neoplasms

abstract

  • LHRHa plus AA treatment suppresses tissue androgens more effectively than LHRHa alone. Intensive intratumoral androgen suppression with LHRHa plus AA before prostatectomy for localized high-risk PCa may reduce tumor burden.

publication date

  • November 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4226804

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.53.4578

PubMed ID

  • 25311217

Additional Document Info

start page

  • 3705

end page

  • 15

volume

  • 32

number

  • 33